References
- Bos, W., A. E. Westra, W. Pinxten, M. P. Mayer, and J. D. Lantos. 2015. Risks in a trial of an innovative treatment of duchenne muscular dystrophy. Pediatrics 136 (6):1173–1177. doi:10.1542/peds.2015-1589.
- Brunner, H. I., C. Abud-Mendoza, D. O. Viola, I. Calvo Penades, D. Levy, J. Anton, J. E. Calderon, V. G. Chasnyk, M. A. Ferrandiz, et al.DO in collaboration with the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)et alSafety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases 202079 10:1340–1348. 10.1136/annrheumdis-2020-217101
- De Santis, F. 2006. Power priors and their use in clinical trials. The American Statistician 60 (2):122–129. http://www.jstor.org/stable/27643749.
- Dunne, J., W. J. Rodriguez, M. D. Murphy, B. N. Beasley, G. J. Burckart, J. D. Filie …, and L. L. Lewis, H. C. Sachs, P. H. Sheridan, P. Starke, L. P. Yao. 2011. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 128 (5):e1242–1249. doi:10.1542/peds.2010-3487.
- EMA Benlysta Assessment report https://www.ema.europa.eu/en/documents/variation-report/benlysta-h-c-2015-ii-0062-epar-assessment-report-variation_en.pdf
- EMA points to consider on application with 1.Meta-Analyses 2 One Pivotal Study.https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-application-1meta-analyses-2one-pivotal-study_en.pdf.
- EMA Reflection paper on the use of extrapolation in the development of medicines for paediatrics https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-reflection-paper-use-extrapolation-development-medicines-paediatrics-revision-1_en.pdf
- FDA Complex Innovative Trial Design Program https://www.fda.gov/drugs/development-resources/complex-innovative-trial-design-pilot-meeting-program
- FDA draft guidance considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological Products https://www.fda.gov/media/154714/download
- FDA draft guidance meta-analyses of randomized controlled clinical trials to evaluate the safety of human drugs or biological products Guidance for Industry https://www.fda.gov/media/117976/download
- FDA draft guidance real-world data: assessing electronic health records and medical claims data to support regulatory decision making for drug and biological Products https://www.fda.gov/media/152503/download
- FDA-M CERSI: Advancing the development of pediatric therapeutics (ADEPT) complex innovative trial design public Workshop https://www.fda.gov/drugs/news-events-human-drugs/fda-m-cersi-advancing-development-pediatric-therapeutics-complex-innovative-trial-design-public
- FDA package insert for Fingolimod (as of December 2019) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf
- FDA package insert for ofatumumab (as of August 2020) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125326s070lbl.pdf
- FDA review of benlysta (belimumab) for intravenous infusion in children 5 to 17 years of age with SLE https://www.fda.gov/media/127912/download
- Gamalo-Siebers, M., L. Hampson, K. Kordy, S. Weber, R. M. Nelson, and R. Portman. 2019. Incorporating innovative techniques toward extrapolation and efficient pediatric drug development. Therapeutic Innovation & Regulatory Science 53 (5):567–578. doi:10.1177/2168479019842541.
- Goodman, S. N., and J. T. Sladky. 2005. A Bayesian approach to randomized controlled trials in children utilizing information from adults: The case of Guillain-Barre. Clinical Trials 2 (4):305–310. doi:10.1191/1740774505cn102oa.
- Greenhouse, J. B., and H. Seltman. 2005. Using prior distributions to synthesize historical evidence: Comments on the Goodman–Sladky case study of IVIg in Guillain–Barré syndrome. Clinical Trials 2 (4):311–318. doi:10.1191/1740774505cn095oa.
- Hobbs, B. P., D. J. Sargent, and B. P. Carlin. 2012. Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models. Bayesian Analysis 7 (3):639–674. doi:10.1214/12-BA722.
- Hoeting, J. A., D. Madigan, A. E. Raftery, and C. T. Volinsky. 1999. Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and EI George, and a rejoinder by the authors. Statistical Science 14 (4): 382–417. Bayesian model averaging: A tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors. 10.1214/ss/1009212519.
- Ibrahim, J. G., M. -H. Chen, Y. Gwon, and F. Chen. 2015. The power prior: Theory and applications. Statistics in Medicine 34 3724–3749. 10.1002/sim.6728.
- International Conference on Harmonisation (ICH), E11A pediatric extrapolation, draft version. Retrieved November 16, 2022, from https://database.ich.org/sites/default/files/ICH_E11A_Document_Step2_Guideline_2022_0404_0.pdf
- Momper, J. D., D. J. Green, K. Park, G. J. Burckart, and D. L. Snyder. 2021. Ethical considerations for pediatric placebo-controlled trials: fda outcomes and perspectives. Therapeutic Innovation & Regulatory Science 55 (2):282–303. doi:https://doi.org/10.1007/s43441-020-00214-3.
- Morgan, M. G. 2014. Use (and abuse) of expert elicitation in support of decision making for public policy. Proceedings of the National Academy of Sciences 111 (20):7176–7184. doi:10.1073/pnas.1319946111.
- Morita, S., P. F. Thall, and P. Müller 2008, . Determining the effective sample size of a parametric prior. ( Epub 2007 Aug 30. PMID: 17764481; PMCID: PMC3081791) Biometrics 64 (2):595–602. doi: 10.1111/j.1541-0420.2007.00888.x.
- Neuenschwander, B., S. Weber, H. Schmidli, and A. O’hagan 2020. Predictively consistent prior effective sample sizes. Biometrics 76:578–587. doi: 10.1111/biom.13252.
- O’Hagan, A., C. E. Buck, A. Daneshkhah, J. R. Eiser, P. H. Garthwaite, D. J. Jenkinson, and T. Rakow. 2006. Uncertain judgements: Eliciting experts’ probabilities. ISBN-13 9780470029992. John Wiley & Sons.
- Ollivier, C., H. Sun, W. Amchin, M. Beghetti, R. M. F. Berger, S. Breitenstein, C. Garnett, N. Gullberg, P. Hassel, D. Ivy, et al. 2019. New strategies for the conduct of clinical trials in pediatric pulmonary arterial hypertension: outcome of a multistakeholder meeting with patients, academia. Industry, and Regulators, Held at the European Medicines Agency on MondayJournal of the American Heart Association 8(10): e011306. June 12, 2017. doi:10.1161/JAHA.118.011306.
- Pennello, G., and L. Thompson. 2007. Experience with reviewing Bayesian medical device trials. Journal of Biopharmaceutical Statistics 18 (1):81–115. doi:10.1080/10543400701668274.
- Ruberg, S. J., F. E. Harrell Jr, M. Gamalo-Siebers, L. LaVange, J. Jack Lee, K. Price, and C. Peck. 2019. Inference and decision making for 21st-century drug development and approval. The American Statistician 73 (sup1):319–327. doi:10.1080/00031305.2019.1566091.
- Schmidli, H., S. Gsteiger, S. Roychoudhury, A. O’Hagan, D. Spiegelhalter, and B. Neuenschwander. 2014. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics 70 (4):1023–1032. doi:10.1111/biom.12242.
- Schmidli, H., D. A. Häring, M. Thomas, A. Cassidy, S. Weber, and F. Bretz. 2020. Beyond randomized clinical trials: Use of external controls. Clinical Pharmacology & Therapeutics 107 (4):806–816. doi:https://doi.org/10.1002/cpt.1723.
- Sun, H., J. W. Temeck, W. Chambers, G. Perkins, R. Bonnel, and D. Murphy. 2018. Extrapolation of efficacy in pediatric drug development and evidence-based medicine: Progress and lessons learned. Therapeutic Innovation & Regulatory Science 52 (2):199–205. doi:10.1177/2168479017725558.
- Wadsworth, I., L. V. Hampson, and T. Jaki. 2018. Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods. Statistical Methods in Medical Research 27 (2):398–413. doi:10.1177/0962280216631359.
- Weber, S., Y. Li, J. W. Seaman, T. Kakizume, and H. Schmidli. 2021. Applying meta-analytic-predictive priors with the r Bayesian evidence synthesis tools. Journal of Statistical Software 100 (19):1–32. doi:10.18637/jss.v100.i19.
- Ye, J., and J. Travis, “A Bayesian approach to incorporating adult clinical data into pediatric clinical trials”, Pediatric Trial Design and Modeling: Moving into the Next Decade, September 2017 https://www.fda.gov/media/107649/download